| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 27 | 2024 | 237 | 6.010 |
Why?
|
| Obesity | 42 | 2025 | 367 | 5.390 |
Why?
|
| Metabolic Syndrome | 19 | 2024 | 64 | 5.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 20 | 2025 | 139 | 4.380 |
Why?
|
| Adipocytes | 14 | 2022 | 23 | 3.770 |
Why?
|
| Alkaline Phosphatase | 10 | 2022 | 18 | 3.500 |
Why?
|
| Body Composition | 19 | 2022 | 153 | 3.080 |
Why?
|
| Humans | 146 | 2025 | 14537 | 2.960 |
Why?
|
| Female | 111 | 2025 | 9103 | 2.710 |
Why?
|
| Body Mass Index | 33 | 2025 | 321 | 2.640 |
Why?
|
| Middle Aged | 75 | 2025 | 3601 | 2.490 |
Why?
|
| Vitamin D | 7 | 2024 | 41 | 2.360 |
Why?
|
| Cross-Sectional Studies | 43 | 2025 | 1422 | 2.360 |
Why?
|
| Adult | 88 | 2025 | 5913 | 2.350 |
Why?
|
| Menopause | 7 | 2024 | 24 | 2.340 |
Why?
|
| HIV Infections | 30 | 2024 | 5097 | 2.320 |
Why?
|
| Lipid Metabolism | 14 | 2019 | 44 | 2.110 |
Why?
|
| Risk Factors | 44 | 2025 | 1475 | 2.060 |
Why?
|
| Insulin Resistance | 15 | 2022 | 79 | 2.030 |
Why?
|
| South Africa | 72 | 2025 | 7596 | 1.810 |
Why?
|
| Insulin | 22 | 2022 | 73 | 1.810 |
Why?
|
| Adipose Tissue | 15 | 2020 | 52 | 1.770 |
Why?
|
| Prevalence | 34 | 2025 | 1192 | 1.710 |
Why?
|
| Adiposity | 11 | 2022 | 96 | 1.700 |
Why?
|
| Hypertension | 15 | 2025 | 419 | 1.700 |
Why?
|
| Biomarkers | 8 | 2022 | 327 | 1.650 |
Why?
|
| Male | 71 | 2025 | 6754 | 1.600 |
Why?
|
| Blood Pressure | 16 | 2025 | 317 | 1.550 |
Why?
|
| Body Fat Distribution | 6 | 2022 | 16 | 1.460 |
Why?
|
| Urban Population | 14 | 2023 | 257 | 1.390 |
Why?
|
| Parathyroid Hormone | 3 | 2015 | 13 | 1.390 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2024 | 22 | 1.380 |
Why?
|
| Aging | 5 | 2022 | 109 | 1.260 |
Why?
|
| Blood Glucose | 17 | 2023 | 107 | 1.200 |
Why?
|
| Lipids | 14 | 2022 | 81 | 1.200 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 27 | 1.190 |
Why?
|
| Africa South of the Sahara | 17 | 2025 | 353 | 1.180 |
Why?
|
| Adipogenesis | 7 | 2019 | 9 | 1.160 |
Why?
|
| Postmenopause | 3 | 2024 | 11 | 1.140 |
Why?
|
| 3T3-L1 Cells | 6 | 2019 | 10 | 1.120 |
Why?
|
| Cognition | 3 | 2022 | 75 | 1.070 |
Why?
|
| Animals | 20 | 2022 | 1081 | 1.030 |
Why?
|
| Rural Population | 11 | 2019 | 654 | 1.000 |
Why?
|
| Callilepis | 2 | 2022 | 3 | 0.990 |
Why?
|
| Dyslipidemias | 6 | 2025 | 57 | 0.980 |
Why?
|
| Senecio | 2 | 2022 | 3 | 0.980 |
Why?
|
| Atherosclerosis | 6 | 2022 | 100 | 0.960 |
Why?
|
| Waist Circumference | 7 | 2025 | 60 | 0.910 |
Why?
|
| Antiretroviral Therapy, Highly Active | 11 | 2019 | 472 | 0.910 |
Why?
|
| Autoantibodies | 3 | 2021 | 49 | 0.910 |
Why?
|
| Stavudine | 4 | 2013 | 78 | 0.910 |
Why?
|
| Carotid Intima-Media Thickness | 8 | 2023 | 108 | 0.900 |
Why?
|
| Diabetes Mellitus | 10 | 2024 | 146 | 0.890 |
Why?
|
| Mice | 9 | 2019 | 135 | 0.890 |
Why?
|
| Pregnancy | 13 | 2021 | 1862 | 0.800 |
Why?
|
| Subcutaneous Fat | 3 | 2022 | 9 | 0.780 |
Why?
|
| Cognition Disorders | 1 | 2022 | 36 | 0.760 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2024 | 198 | 0.760 |
Why?
|
| Vitamins | 1 | 2021 | 23 | 0.750 |
Why?
|
| Quality of Life | 2 | 2022 | 177 | 0.750 |
Why?
|
| Young Adult | 14 | 2024 | 2498 | 0.730 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.720 |
Why?
|
| Life Style | 5 | 2018 | 86 | 0.720 |
Why?
|
| Anti-Retroviral Agents | 7 | 2019 | 551 | 0.710 |
Why?
|
| African Americans | 4 | 2021 | 47 | 0.690 |
Why?
|
| Overweight | 5 | 2018 | 87 | 0.690 |
Why?
|
| Adrenal Cortex | 1 | 2019 | 2 | 0.670 |
Why?
|
| Cholesterol Esters | 1 | 2019 | 2 | 0.670 |
Why?
|
| Cell Differentiation | 9 | 2022 | 20 | 0.670 |
Why?
|
| Cell Culture Techniques | 2 | 2019 | 7 | 0.660 |
Why?
|
| Thinness | 2 | 2018 | 18 | 0.650 |
Why?
|
| Bone Density | 4 | 2023 | 107 | 0.640 |
Why?
|
| Aged | 19 | 2025 | 1740 | 0.640 |
Why?
|
| Gastroesophageal Reflux | 1 | 2018 | 3 | 0.640 |
Why?
|
| Genome-Wide Association Study | 4 | 2023 | 106 | 0.630 |
Why?
|
| Lipodystrophy | 2 | 2009 | 7 | 0.630 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 29 | 0.630 |
Why?
|
| HIV | 6 | 2023 | 380 | 0.620 |
Why?
|
| Infant, Low Birth Weight | 3 | 2012 | 35 | 0.620 |
Why?
|
| Fatty Liver | 1 | 2018 | 8 | 0.590 |
Why?
|
| PPAR gamma | 2 | 2017 | 3 | 0.590 |
Why?
|
| Adipokines | 3 | 2019 | 11 | 0.570 |
Why?
|
| Glucose Tolerance Test | 10 | 2017 | 33 | 0.570 |
Why?
|
| Longitudinal Studies | 14 | 2025 | 435 | 0.560 |
Why?
|
| Cytoplasm | 1 | 2017 | 7 | 0.560 |
Why?
|
| Anthropometry | 10 | 2018 | 102 | 0.560 |
Why?
|
| Weight Gain | 5 | 2019 | 77 | 0.550 |
Why?
|
| Lipocalin-2 | 1 | 2016 | 1 | 0.540 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 15 | 0.540 |
Why?
|
| Metabolic Diseases | 4 | 2019 | 30 | 0.520 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 56 | 0.510 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 1324 | 0.510 |
Why?
|
| Phenotype | 4 | 2025 | 158 | 0.500 |
Why?
|
| Intra-Abdominal Fat | 4 | 2022 | 15 | 0.500 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 19 | 0.500 |
Why?
|
| Skin | 2 | 2014 | 38 | 0.500 |
Why?
|
| Insulin-Secreting Cells | 2 | 2021 | 6 | 0.500 |
Why?
|
| Adenine | 2 | 2013 | 91 | 0.500 |
Why?
|
| Sleep | 1 | 2015 | 36 | 0.490 |
Why?
|
| Absorptiometry, Photon | 6 | 2022 | 85 | 0.490 |
Why?
|
| Sex Factors | 7 | 2023 | 227 | 0.490 |
Why?
|
| Islets of Langerhans | 4 | 2000 | 10 | 0.480 |
Why?
|
| Ovary | 1 | 2014 | 5 | 0.480 |
Why?
|
| Psoriasis | 3 | 2019 | 10 | 0.470 |
Why?
|
| Reproduction | 1 | 2014 | 25 | 0.470 |
Why?
|
| Sunlight | 1 | 2014 | 3 | 0.470 |
Why?
|
| Self Report | 3 | 2022 | 114 | 0.470 |
Why?
|
| Premenopause | 2 | 2024 | 14 | 0.460 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 25 | 0.450 |
Why?
|
| Dietary Supplements | 1 | 2014 | 40 | 0.450 |
Why?
|
| Sodium, Dietary | 2 | 2025 | 14 | 0.450 |
Why?
|
| Exercise | 6 | 2023 | 205 | 0.420 |
Why?
|
| Plants, Medicinal | 2 | 2002 | 7 | 0.400 |
Why?
|
| Organophosphonates | 1 | 2012 | 45 | 0.400 |
Why?
|
| Infant, Newborn | 8 | 2019 | 1479 | 0.400 |
Why?
|
| Lactic Acid | 5 | 2020 | 34 | 0.400 |
Why?
|
| Glucose | 11 | 2022 | 45 | 0.400 |
Why?
|
| Cohort Studies | 7 | 2022 | 967 | 0.400 |
Why?
|
| Plant Extracts | 2 | 2022 | 32 | 0.390 |
Why?
|
| Developing Countries | 4 | 2023 | 400 | 0.390 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 118 | 0.390 |
Why?
|
| Smoking | 5 | 2021 | 100 | 0.390 |
Why?
|
| Genotype | 4 | 2024 | 442 | 0.390 |
Why?
|
| Polylysine | 2 | 2009 | 2 | 0.390 |
Why?
|
| Heparin | 2 | 2009 | 5 | 0.390 |
Why?
|
| Cholesterol, LDL | 5 | 2025 | 150 | 0.380 |
Why?
|
| Chronic Disease | 1 | 2012 | 107 | 0.380 |
Why?
|
| Alginates | 2 | 2009 | 34 | 0.380 |
Why?
|
| Social Class | 3 | 2022 | 73 | 0.380 |
Why?
|
| Glycated Hemoglobin A | 4 | 2021 | 24 | 0.370 |
Why?
|
| Levamisole | 4 | 2019 | 6 | 0.360 |
Why?
|
| Leptin | 5 | 2015 | 26 | 0.360 |
Why?
|
| Gestational Age | 3 | 2021 | 80 | 0.360 |
Why?
|
| Fatty Acids, Nonesterified | 8 | 2002 | 11 | 0.360 |
Why?
|
| Abdominal Fat | 2 | 2011 | 6 | 0.360 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2022 | 25 | 0.360 |
Why?
|
| Waist-Hip Ratio | 6 | 2025 | 29 | 0.350 |
Why?
|
| Hepatocytes | 2 | 2017 | 19 | 0.350 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 370 | 0.350 |
Why?
|
| Prospective Studies | 6 | 2022 | 1160 | 0.350 |
Why?
|
| Birth Weight | 4 | 2012 | 80 | 0.340 |
Why?
|
| Socioeconomic Factors | 6 | 2018 | 411 | 0.340 |
Why?
|
| Kenya | 4 | 2023 | 183 | 0.330 |
Why?
|
| Adolescent | 9 | 2024 | 2985 | 0.330 |
Why?
|
| Membranes, Artificial | 1 | 2009 | 6 | 0.320 |
Why?
|
| Body Size | 2 | 2021 | 15 | 0.320 |
Why?
|
| Interleukin-6 | 3 | 2019 | 51 | 0.320 |
Why?
|
| Child | 7 | 2019 | 2242 | 0.320 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2019 | 6 | 0.310 |
Why?
|
| Histidine | 4 | 2014 | 9 | 0.310 |
Why?
|
| Integrin beta3 | 1 | 2008 | 1 | 0.310 |
Why?
|
| Growth | 1 | 2008 | 14 | 0.300 |
Why?
|
| Ghana | 7 | 2022 | 67 | 0.300 |
Why?
|
| Blood Platelets | 1 | 2008 | 30 | 0.300 |
Why?
|
| Triglycerides | 7 | 2025 | 47 | 0.300 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2022 | 656 | 0.300 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 99 | 0.290 |
Why?
|
| Sodium | 2 | 2025 | 30 | 0.290 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2025 | 27 | 0.290 |
Why?
|
| Azo Compounds | 2 | 2019 | 6 | 0.290 |
Why?
|
| Child, Preschool | 5 | 2019 | 1748 | 0.290 |
Why?
|
| Awareness | 2 | 2017 | 18 | 0.290 |
Why?
|
| Hep G2 Cells | 2 | 2017 | 14 | 0.290 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 3 | 0.290 |
Why?
|
| Rural Health Services | 2 | 2017 | 48 | 0.280 |
Why?
|
| Age Factors | 5 | 2019 | 370 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 36 | 0.280 |
Why?
|
| Child Development | 1 | 2008 | 93 | 0.280 |
Why?
|
| Health Behavior | 2 | 2018 | 79 | 0.280 |
Why?
|
| Bilirubin | 1 | 2006 | 3 | 0.270 |
Why?
|
| Isoenzymes | 1 | 2006 | 7 | 0.270 |
Why?
|
| Serum Albumin | 1 | 2006 | 6 | 0.270 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 23 | 0.270 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 2 | 0.270 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 22 | 0.260 |
Why?
|
| Urban Health | 3 | 2017 | 78 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 125 | 0.250 |
Why?
|
| Case-Control Studies | 6 | 2024 | 480 | 0.250 |
Why?
|
| Cytokines | 1 | 2006 | 107 | 0.250 |
Why?
|
| Genomics | 2 | 2018 | 109 | 0.250 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2025 | 8 | 0.240 |
Why?
|
| Africa | 3 | 2022 | 376 | 0.240 |
Why?
|
| Receptors, Calcitriol | 1 | 2024 | 4 | 0.240 |
Why?
|
| Diet | 3 | 2015 | 109 | 0.240 |
Why?
|
| Cell Line | 2 | 2019 | 93 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 176 | 0.240 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2002 | 51 | 0.240 |
Why?
|
| Climacteric | 1 | 2024 | 1 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2014 | 529 | 0.230 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 55 | 0.230 |
Why?
|
| India | 2 | 2014 | 62 | 0.230 |
Why?
|
| Fasting | 6 | 2021 | 16 | 0.230 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 8 | 0.220 |
Why?
|
| Health Status | 3 | 2021 | 111 | 0.220 |
Why?
|
| Infant | 5 | 2019 | 2244 | 0.220 |
Why?
|
| Sex Distribution | 3 | 2018 | 89 | 0.220 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 563 | 0.210 |
Why?
|
| Helminthiasis | 2 | 2013 | 7 | 0.210 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2023 | 3 | 0.210 |
Why?
|
| Rwanda | 7 | 2014 | 30 | 0.210 |
Why?
|
| Linear Models | 3 | 2019 | 83 | 0.210 |
Why?
|
| Kidney Diseases | 2 | 2020 | 38 | 0.210 |
Why?
|
| Urinalysis | 1 | 2022 | 15 | 0.210 |
Why?
|
| Medicine, African Traditional | 1 | 2002 | 25 | 0.210 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2002 | 10 | 0.210 |
Why?
|
| Waist-Height Ratio | 1 | 2022 | 4 | 0.210 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2022 | 4 | 0.200 |
Why?
|
| Viral Load | 4 | 2022 | 819 | 0.200 |
Why?
|
| Osteoporotic Fractures | 1 | 2022 | 7 | 0.200 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2022 | 11 | 0.200 |
Why?
|
| Risk | 2 | 2013 | 87 | 0.200 |
Why?
|
| Uterus | 1 | 2002 | 20 | 0.200 |
Why?
|
| ROC Curve | 1 | 2022 | 51 | 0.200 |
Why?
|
| Noncommunicable Diseases | 1 | 2024 | 77 | 0.200 |
Why?
|
| Albuminuria | 2 | 2022 | 20 | 0.200 |
Why?
|
| Regression Analysis | 4 | 2017 | 133 | 0.200 |
Why?
|
| Infant, Premature | 1 | 2002 | 56 | 0.200 |
Why?
|
| Anaerobic Threshold | 2 | 2020 | 2 | 0.200 |
Why?
|
| Adonis | 1 | 2022 | 2 | 0.200 |
Why?
|
| Solid Phase Extraction | 1 | 2022 | 3 | 0.200 |
Why?
|
| Sex Characteristics | 3 | 2014 | 43 | 0.200 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2022 | 5 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 7 | 0.200 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2022 | 18 | 0.200 |
Why?
|
| Mass Screening | 1 | 2024 | 245 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 10 | 0.190 |
Why?
|
| Carotid Artery Diseases | 1 | 2022 | 34 | 0.190 |
Why?
|
| Liver | 4 | 2018 | 74 | 0.190 |
Why?
|
| Zinc Transporter 8 | 1 | 2021 | 2 | 0.190 |
Why?
|
| Comorbidity | 4 | 2019 | 188 | 0.190 |
Why?
|
| Acculturation | 1 | 2001 | 1 | 0.190 |
Why?
|
| Health Planning | 1 | 2001 | 13 | 0.190 |
Why?
|
| Social Change | 1 | 2001 | 14 | 0.190 |
Why?
|
| Energy Metabolism | 1 | 2001 | 13 | 0.180 |
Why?
|
| Pyrophosphatases | 1 | 2020 | 1 | 0.180 |
Why?
|
| Geography | 2 | 2018 | 60 | 0.180 |
Why?
|
| Stromal Cells | 2 | 2011 | 2 | 0.180 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2020 | 2 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 59 | 0.180 |
Why?
|
| Proinsulin | 3 | 2000 | 3 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2021 | 14 | 0.180 |
Why?
|
| Amino Acids, Aromatic | 1 | 2020 | 3 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2020 | 4 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 62 | 0.180 |
Why?
|
| Ultrasonography | 2 | 2021 | 77 | 0.180 |
Why?
|
| Coinfection | 2 | 2013 | 276 | 0.180 |
Why?
|
| Incidence | 5 | 2025 | 685 | 0.180 |
Why?
|
| Lipolysis | 1 | 2000 | 1 | 0.170 |
Why?
|
| Glycerol | 4 | 2001 | 8 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 61 | 0.170 |
Why?
|
| Burkina Faso | 4 | 2021 | 29 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 44 | 0.170 |
Why?
|
| Age of Onset | 1 | 2019 | 32 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2019 | 2 | 0.170 |
Why?
|
| Coloring Agents | 1 | 2019 | 1 | 0.170 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2019 | 7 | 0.170 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 13 | 0.170 |
Why?
|
| Epitopes | 2 | 2005 | 97 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2019 | 23 | 0.170 |
Why?
|
| DNA Methylation | 1 | 2019 | 19 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2019 | 35 | 0.170 |
Why?
|
| C-Reactive Protein | 3 | 2019 | 96 | 0.170 |
Why?
|
| United States | 2 | 2017 | 132 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 150 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2018 | 325 | 0.160 |
Why?
|
| Adiponectin | 2 | 2012 | 15 | 0.160 |
Why?
|
| Thrombomodulin | 1 | 2019 | 1 | 0.160 |
Why?
|
| Cadherins | 1 | 2019 | 2 | 0.160 |
Why?
|
| Oxazines | 1 | 2019 | 81 | 0.160 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 20 | 0.160 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 3 | 0.160 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 38 | 0.160 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 21 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2019 | 26 | 0.160 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 20 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 64 | 0.150 |
Why?
|
| Motor Activity | 2 | 2015 | 46 | 0.150 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2018 | 7 | 0.150 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 12 | 0.150 |
Why?
|
| Lipid Droplets | 1 | 2017 | 1 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 4 | 0.150 |
Why?
|
| RNA, Messenger | 1 | 2017 | 32 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 41 | 0.140 |
Why?
|
| Gene Frequency | 2 | 2008 | 122 | 0.140 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 39 | 0.140 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2017 | 13 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 74 | 0.140 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 49 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 43 | 0.140 |
Why?
|
| Glucose Intolerance | 1 | 2017 | 5 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 55 | 0.140 |
Why?
|
| Biochemistry | 1 | 1996 | 1 | 0.130 |
Why?
|
| Awards and Prizes | 1 | 1996 | 2 | 0.130 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 4 | 0.130 |
Why?
|
| Rural Health | 1 | 2017 | 118 | 0.130 |
Why?
|
| Cholesterol, HDL | 3 | 2019 | 32 | 0.130 |
Why?
|
| Cities | 1 | 2016 | 37 | 0.130 |
Why?
|
| DNA, Mitochondrial | 2 | 2013 | 31 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 18 | 0.130 |
Why?
|
| Culture Media | 2 | 2006 | 15 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 16 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2015 | 6 | 0.120 |
Why?
|
| Inflammation | 2 | 2013 | 104 | 0.120 |
Why?
|
| Body Weight | 3 | 2018 | 111 | 0.120 |
Why?
|
| Flow Cytometry | 3 | 2011 | 67 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 199 | 0.120 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2014 | 11 | 0.120 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 4 | 0.120 |
Why?
|
| Estradiol | 1 | 2014 | 18 | 0.120 |
Why?
|
| Anthelmintics | 1 | 2014 | 9 | 0.120 |
Why?
|
| Disease | 1 | 2014 | 12 | 0.120 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Calcifediol | 1 | 2014 | 6 | 0.120 |
Why?
|
| Antimalarials | 1 | 2014 | 33 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2019 | 64 | 0.110 |
Why?
|
| Seasons | 1 | 2014 | 154 | 0.110 |
Why?
|
| Phosphorous Acids | 1 | 2013 | 14 | 0.110 |
Why?
|
| Cattle | 2 | 2009 | 28 | 0.110 |
Why?
|
| Malaria, Falciparum | 1 | 2013 | 39 | 0.110 |
Why?
|
| Osteoblasts | 1 | 2012 | 1 | 0.110 |
Why?
|
| Endocrine System | 1 | 2012 | 3 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 5 | 0.110 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2012 | 2 | 0.100 |
Why?
|
| Potassium | 2 | 2022 | 25 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 22 | 0.100 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2002 | 5 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 20 | 0.100 |
Why?
|
| Cell Survival | 2 | 2002 | 48 | 0.100 |
Why?
|
| C-Peptide | 5 | 2022 | 13 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2012 | 27 | 0.100 |
Why?
|
| Education | 1 | 2011 | 22 | 0.090 |
Why?
|
| Tenofovir | 1 | 2012 | 171 | 0.090 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2017 | 543 | 0.090 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 2006 | 3 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2005 | 142 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 151 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2017 | 889 | 0.090 |
Why?
|
| Blood Flow Velocity | 2 | 2008 | 17 | 0.090 |
Why?
|
| Malaria | 1 | 2012 | 213 | 0.090 |
Why?
|
| Cholesterol | 2 | 2008 | 38 | 0.080 |
Why?
|
| Absorption | 1 | 2009 | 6 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 46 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 63 | 0.080 |
Why?
|
| Kinetics | 1 | 2009 | 65 | 0.080 |
Why?
|
| Thromboxane A2 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Adenosine Diphosphate | 1 | 2008 | 4 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 12 | 0.080 |
Why?
|
| Diet, Protein-Restricted | 3 | 1997 | 3 | 0.080 |
Why?
|
| Collagen | 1 | 2008 | 23 | 0.080 |
Why?
|
| Metformin | 1 | 2008 | 3 | 0.080 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 14 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 30 | 0.070 |
Why?
|
| Body Constitution | 3 | 2002 | 8 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 171 | 0.070 |
Why?
|
| Base Sequence | 2 | 2005 | 149 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2008 | 14 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2019 | 225 | 0.070 |
Why?
|
| Alleles | 1 | 2008 | 143 | 0.070 |
Why?
|
| Time Factors | 2 | 2010 | 507 | 0.070 |
Why?
|
| Pregnancy, Animal | 2 | 1997 | 2 | 0.070 |
Why?
|
| Animals, Newborn | 2 | 1997 | 6 | 0.070 |
Why?
|
| Lactation | 2 | 1997 | 12 | 0.070 |
Why?
|
| Eating | 1 | 2006 | 16 | 0.070 |
Why?
|
| Intracellular Fluid | 1 | 2006 | 3 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2006 | 6 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2006 | 13 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 468 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2006 | 16 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 187 | 0.070 |
Why?
|
| Extracorporeal Circulation | 1 | 2006 | 2 | 0.070 |
Why?
|
| Bioreactors | 1 | 2006 | 2 | 0.070 |
Why?
|
| Food | 2 | 2002 | 11 | 0.060 |
Why?
|
| Insulin Antibodies | 1 | 2005 | 1 | 0.060 |
Why?
|
| HIV-1 | 2 | 2011 | 1260 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2005 | 4 | 0.060 |
Why?
|
| Prediabetic State | 1 | 2005 | 3 | 0.060 |
Why?
|
| Sequence Alignment | 1 | 2005 | 59 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 40 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2024 | 22 | 0.060 |
Why?
|
| Rats | 4 | 2010 | 130 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 263 | 0.060 |
Why?
|
| Weight Loss | 1 | 2004 | 12 | 0.060 |
Why?
|
| Age Distribution | 2 | 2018 | 107 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 8 | 0.060 |
Why?
|
| Ankle Brachial Index | 1 | 2023 | 2 | 0.060 |
Why?
|
| Women's Health | 1 | 2024 | 41 | 0.060 |
Why?
|
| Glucose Clamp Technique | 2 | 2000 | 4 | 0.050 |
Why?
|
| Uganda | 1 | 2023 | 197 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2023 | 18 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 3 | 0.050 |
Why?
|
| Necrosis | 1 | 2002 | 7 | 0.050 |
Why?
|
| Urine Specimen Collection | 1 | 2022 | 6 | 0.050 |
Why?
|
| Perilipins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Wheat Germ Agglutinins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 13 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 17 | 0.050 |
Why?
|
| Sugars | 1 | 2022 | 14 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2023 | 42 | 0.050 |
Why?
|
| Nutritional Status | 2 | 2017 | 76 | 0.050 |
Why?
|
| Radius | 1 | 2022 | 9 | 0.050 |
Why?
|
| Tibia | 1 | 2022 | 14 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.050 |
Why?
|
| DNA | 1 | 2002 | 73 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Gastrointestinal Hormones | 1 | 2022 | 4 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor, Endocrine-Gland-Derived | 1 | 2022 | 4 | 0.050 |
Why?
|
| Sorting Nexins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Histones | 1 | 2022 | 7 | 0.050 |
Why?
|
| Genome | 1 | 2022 | 9 | 0.050 |
Why?
|
| Autoantigens | 1 | 2022 | 10 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2001 | 1 | 0.050 |
Why?
|
| Pyrrolizidine Alkaloids | 1 | 2001 | 1 | 0.050 |
Why?
|
| Medicine, Traditional | 1 | 2001 | 7 | 0.050 |
Why?
|
| Apoptosis | 1 | 2001 | 40 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2001 | 12 | 0.050 |
Why?
|
| South America | 1 | 2020 | 27 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 1992 | 21 | 0.050 |
Why?
|
| Energy Intake | 1 | 2020 | 24 | 0.050 |
Why?
|
| Protein Precursors | 1 | 2000 | 22 | 0.040 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2020 | 6 | 0.040 |
Why?
|
| Swine | 2 | 1990 | 49 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 17 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2019 | 2 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 133 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 17 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2019 | 8 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 55 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 149 | 0.040 |
Why?
|
| Growth Disorders | 2 | 1996 | 56 | 0.040 |
Why?
|
| Rats, Wistar | 3 | 2010 | 13 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 254 | 0.040 |
Why?
|
| Skinfold Thickness | 1 | 1998 | 6 | 0.040 |
Why?
|
| Environment | 1 | 2018 | 22 | 0.040 |
Why?
|
| Glycemic Index | 1 | 2018 | 2 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 253 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 12 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 9 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 37 | 0.040 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 1997 | 1 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 1997 | 2 | 0.040 |
Why?
|
| Survival Rate | 1 | 2017 | 96 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.040 |
Why?
|
| Urban Health Services | 1 | 2017 | 10 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 17 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2017 | 31 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 1996 | 4 | 0.030 |
Why?
|
| Glucokinase | 1 | 1996 | 1 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1996 | 22 | 0.030 |
Why?
|
| United Kingdom | 1 | 1996 | 33 | 0.030 |
Why?
|
| Longevity | 1 | 1996 | 14 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 91 | 0.030 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 71 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 203 | 0.030 |
Why?
|
| Fetus | 1 | 1995 | 8 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 217 | 0.030 |
Why?
|
| Pancreas | 2 | 1996 | 5 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2014 | 9 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2017 | 240 | 0.030 |
Why?
|
| Walking | 1 | 2014 | 14 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 11 | 0.030 |
Why?
|
| England | 1 | 2014 | 15 | 0.030 |
Why?
|
| Health | 1 | 2014 | 11 | 0.030 |
Why?
|
| Genetics, Medical | 1 | 2014 | 21 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 154 | 0.030 |
Why?
|
| Sheep | 1 | 1994 | 9 | 0.030 |
Why?
|
| Horses | 1 | 1994 | 4 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1994 | 24 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2017 | 799 | 0.030 |
Why?
|
| Models, Molecular | 1 | 1994 | 84 | 0.030 |
Why?
|
| Parasitology | 1 | 2013 | 1 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
| Alkynes | 1 | 2013 | 117 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2013 | 123 | 0.030 |
Why?
|
| Lamivudine | 1 | 2013 | 89 | 0.030 |
Why?
|
| Exercise Test | 1 | 2013 | 13 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Growth Hormone | 1 | 2012 | 2 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2012 | 2 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2013 | 35 | 0.030 |
Why?
|
| Estrogens | 1 | 2012 | 6 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 5 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2013 | 123 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2012 | 20 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2012 | 33 | 0.030 |
Why?
|
| Feces | 1 | 2012 | 30 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2013 | 101 | 0.030 |
Why?
|
| Carbon Isotopes | 2 | 2002 | 5 | 0.030 |
Why?
|
| Blood | 1 | 2012 | 51 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 27 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 9 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 100 | 0.020 |
Why?
|
| Area Under Curve | 2 | 2001 | 20 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 37 | 0.020 |
Why?
|
| Caprylates | 1 | 1990 | 1 | 0.020 |
Why?
|
| Hydroxybutyrates | 1 | 1990 | 1 | 0.020 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 1990 | 1 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1990 | 2 | 0.020 |
Why?
|
| Leucine | 1 | 1990 | 4 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 10 | 0.020 |
Why?
|
| Arginine | 1 | 1990 | 5 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1990 | 11 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 54 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 79 | 0.020 |
Why?
|
| Amylases | 1 | 1989 | 1 | 0.020 |
Why?
|
| Somatostatin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1989 | 2 | 0.020 |
Why?
|
| Glucagon | 1 | 1989 | 4 | 0.020 |
Why?
|
| Postprandial Period | 2 | 1999 | 4 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2008 | 3 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2008 | 29 | 0.020 |
Why?
|
| Psychometrics | 1 | 2008 | 22 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2008 | 3 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 19 | 0.020 |
Why?
|
| Aorta | 1 | 2008 | 43 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2007 | 27 | 0.020 |
Why?
|
| Microspheres | 1 | 2006 | 8 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2005 | 9 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2005 | 17 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 32 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 139 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 73 | 0.020 |
Why?
|
| Caseins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Sucrose | 1 | 2002 | 1 | 0.010 |
Why?
|
| Viscera | 1 | 2002 | 1 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 2002 | 2 | 0.010 |
Why?
|
| Emulsions | 1 | 2002 | 5 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2002 | 7 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 24 | 0.010 |
Why?
|
| Breath Tests | 1 | 2001 | 3 | 0.010 |
Why?
|
| Testosterone | 1 | 2001 | 14 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 2001 | 1 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2001 | 10 | 0.010 |
Why?
|
| Lactates | 1 | 2000 | 1 | 0.010 |
Why?
|
| Microdialysis | 1 | 1998 | 1 | 0.010 |
Why?
|
| Homeostasis | 1 | 1998 | 9 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1997 | 1 | 0.010 |
Why?
|
| Receptor, Insulin | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cell Size | 1 | 1997 | 2 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cell Count | 1 | 1997 | 10 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1997 | 10 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 40 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1996 | 1 | 0.010 |
Why?
|
| Muscle Development | 1 | 1996 | 2 | 0.010 |
Why?
|
| Spleen | 1 | 1996 | 9 | 0.010 |
Why?
|
| Heart | 1 | 1996 | 27 | 0.010 |
Why?
|
| Brain | 1 | 1996 | 53 | 0.010 |
Why?
|
| Kidney | 1 | 1996 | 46 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 77 | 0.010 |
Why?
|
| Lung | 1 | 1996 | 70 | 0.010 |
Why?
|
| Organ Size | 1 | 1995 | 34 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 6 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 385 | 0.010 |
Why?
|